Chaotic neovascularization induced by aggressive fibrosarcoma cells overexpressing S-adenosylmethionine decarboxylase

Auvinen, 1992, Ornithine decarboxylase activity is critical for cell transformation, Nature, 360, 355, 10.1038/360355a0 Auvinen, 1995, Ornithine decarboxylase- and ras-induced cell transformations: reversal by protein tyrosine kinase inhibitors and role of pp130CAS, Mol Cell Biol, 15, 6513, 10.1128/MCB.15.12.6513 Auvinen, 1997, Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice, Cancer Res, 57, 3016 Bergers, 2000, Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis, Nat Cell Biol, 2, 737, 10.1038/35036374 Bergers, 2003, Tumorigenesis and the angiogenic switch, Nat Rev Cancer, 3, 401, 10.1038/nrc1093 Bouck, 1996, How tumors become angiogenic, Adv Cancer Res, 69, 135, 10.1016/S0065-230X(08)60862-3 Brown, 1990, Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines, Cancer Res, 50, 6184 Carew, 2008, The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib, Cancer Res, 68, 4783, 10.1158/0008-5472.CAN-07-6483 Carmeliet, 2000, Angiogenesis in cancer and other diseases, Nature, 407, 249, 10.1038/35025220 Carmeliet, 2005, VEGF as a key mediator of angiogenesis in cancer, Oncology, 69, 4, 10.1159/000088478 Casero, 2007, Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases, Nat Rev Drug Discov, 6, 373, 10.1038/nrd2243 Castle, 1993, High level thrombospondin 1 expression in two NIH 3T3 cloned lines confers serum- and anchorage-independent growth, J Biol Chem, 268, 2899, 10.1016/S0021-9258(18)53858-8 Chang, 2000, Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood, Proc Natl Acad Sci USA, 97, 14608, 10.1073/pnas.97.26.14608 Christian, 2008, Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells, Am J Pathol, 172, 486, 10.2353/ajpath.2008.070623 Dameron, 1994, The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin, Cold Spring Harb Symp Quant Biol, 59, 483, 10.1101/SQB.1994.059.01.053 de Fraipont, 2001, Thrombospondins and tumor angiogenesis, Trends Mol Med, 7, 401, 10.1016/S1471-4914(01)02102-5 di Tomaso, 2005, Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers, Cancer Res, 65, 5740, 10.1158/0008-5472.CAN-04-4552 Egeblad, 2002, New functions for the matrix metalloproteinases in cancer progression, Nat Rev Cancer, 2, 161, 10.1038/nrc745 Fang, 2000, Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model, Proc Natl Acad Sci USA, 97, 3884, 10.1073/pnas.97.8.3884 Ferrara, 2000, VEGF: an update on biological and therapeutic aspects, Curr Opin Biotechnol, 11, 617, 10.1016/S0958-1669(00)00153-1 Ferrara, 2005, Angiogenesis as a therapeutic target, Nature, 438, 967, 10.1038/nature04483 Folberg, 2000, Vasculogenic mimicry and tumor angiogenesis, Am J Pathol, 156, 361, 10.1016/S0002-9440(10)64739-6 Folberg, 2004, Vasculogenic mimicry, APMIS, 112, 508, 10.1111/j.1600-0463.2004.apm11207-0810.x Folberg, 2006, Tumor cell plasticity in uveal melanoma: microenvironment directed dampening of the invasive and metastatic genotype and phenotype accompanies the generation of vasculogenic mimicry patterns, Am J Pathol, 169, 1376, 10.2353/ajpath.2006.060223 Folkman, 2006, Angiogenesis, Annu RevMed, 57, 1, 10.1146/annurev.med.57.121304.131306 Hanahan, 1996, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 86, 353, 10.1016/S0092-8674(00)80108-7 Handsley, 2005, Metalloproteinases and their inhibitors in tumor angiogenesis, Int J Cancer, 115, 849, 10.1002/ijc.20945 Hato, 2008, The role of angiopoietin-like proteins in angiogenesis and metabolism, Trends Cardiovasc Med, 18, 6, 10.1016/j.tcm.2007.10.003 Heby, 1990, Molecular genetics of polyamine synthesis in eukaryotic cells, Trends Biochem Sci, 15, 153, 10.1016/0968-0004(90)90216-X Hillen, 2007, Tumour vascularization: sprouting angiogenesis and beyond, Cancer Metastasis Rev, 26, 489, 10.1007/s10555-007-9094-7 Holtta, 1998, Cell transformation by ornithine decarboxylase is associated with phosphorylation of the transactivation domain of c-jun, Biochem Soc Trans, 26, 621, 10.1042/bst0260621 Humtsoe, 2003, Regulation of cell-cell interactions by phosphatidic acid phosphatase 2b/VCIP, EMBO J, 22, 1539, 10.1093/emboj/cdg165 Jones, 2000, The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling, Dev Dyn, 218, 235, 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.0.CO;2-G Kaariainen, 2006, Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion, J Pathol, 210, 181, 10.1002/path.2045 Kazerounian, 2008, Thrombospondins in cancer, Cell Mol Life Sci, 65, 700, 10.1007/s00018-007-7486-z Kielosto, 2004, Reversible regulation of the transformed phenotype of ornithine decarboxylase- and ras-overexpressing cells by dominant-negative mutants of c-jun, Cancer Res, 64, 3772, 10.1158/0008-5472.CAN-3188-2 Kielosto, 2009, Identification of integrins alpha6 and beta7 as c-jun- and transformation-relevant genes in highly invasive fibrosarcoma cells, Int J Cancer, 125, 1065, 10.1002/ijc.24391 Kucharzewska, 2010, Ornithine decarboxylase and extracellular polyamines regulate microvascular sprouting and actin cytoskeleton dynamics in endothelial cells, Exp Cell Res, 316, 2683, 10.1016/j.yexcr.2010.05.033 Lan, 2000, Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice, Cancer Res, 60, 5696 MacFadyen, 2005, Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium, FEBS Lett, 579, 2569, 10.1016/j.febslet.2005.03.071 Medina, 2007, Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope, J Cell Mol Med, 11, 374, 10.1111/j.1582-4934.2007.00056.x Morgenstern, 1990, Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line, Nucleic Acids Res, 18, 3587, 10.1093/nar/18.12.3587 Nanda, 2006, Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors, Proc Natl Acad Sci USA, 103, 3351, 10.1073/pnas.0511306103 Nozawa, 2006, Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis, Proc Natl Acad Sci USA, 103, 12493, 10.1073/pnas.0601807103 Nummela, 2006, Thymosin beta4 is a determinant of the transformed phenotype and invasiveness of S-adenosylmethionine decarboxylase-transfected fibroblasts, Cancer Res, 66, 701, 10.1158/0008-5472.CAN-05-2421 Nyberg, 2005, Endogenous inhibitors of angiogenesis, Cancer Res, 65, 3967, 10.1158/0008-5472.CAN-04-2427 Orend, 2006, Tenascin-C induced signaling in cancer, Cancer Lett, 244, 143, 10.1016/j.canlet.2006.02.017 O’Rourke, 1992, Thrombospondin 1 and thrombospondin 2 are expressed as both homo- and heterotrimers, J Biol Chem, 267, 24921, 10.1016/S0021-9258(19)73983-0 Paasinen-Sohns, 1997, Cells transformed by ODC, c-HA-ras and v-src exhibit MAP kinase/Erk-independent constitutive phosphorylation of Sos, Raf and c-Jun activation domain, and reduced PDGF receptor expression, Oncogene, 15, 1953, 10.1038/sj.onc.1201366 Paasinen-Sohns, 2000, c-Jun activation-dependent tumorigenic transformation induced paradoxically by overexpression or block of S-adenosylmethionine decarboxylase, J Cell Biol, 151, 801, 10.1083/jcb.151.4.801 Papetti, 2002, Mechanisms of normal and tumor-derived angiogenesis, Am J Physiol Cell Physiol, 282, C947, 10.1152/ajpcell.00389.2001 Pegg, 1988, Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy, Cancer Res, 48, 759 Ravanko, 2000, Loss of p27Kip1 from cyclin E/cyclin-dependent kinase (CDK) 2 but not from cyclin D1/CDK4 complexes in cells transformed by polyamine biosynthetic enzymes, Cancer Res, 60, 5244 Ravanko, 2004, Cysteine cathepsins are central contributors of invasion by cultured adenosylmethionine decarboxylase-transformed rodent fibroblasts, Cancer Res, 64, 8831, 10.1158/0008-5472.CAN-03-2993 Ren, 2006, Regulation of tumor angiogenesis by thrombospondin-1, Biochim Biophys Acta, 1765, 178 Rettig, 1992, Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer, Proc Natl Acad Sci USA, 89, 10832, 10.1073/pnas.89.22.10832 Roberts, 1996, Regulation of tumor growth and metastasis by thrombospondin-1, FASEB J, 10, 1183, 10.1096/fasebj.10.10.8751720 Sheibani, 1995, Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis, Proc Natl Acad Sci USA, 92, 6788, 10.1073/pnas.92.15.6788 Sistonen, 1989, Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase, J Cell Biol, 109, 1911, 10.1083/jcb.109.5.1911 Slack, 1994, Transformation by v-src causes transient induction followed by repression of mouse thrombospondin-1, Cell Growth Differ, 5, 1373 Soikkeli, 2007, Systematic search for the best gene expression markers for melanoma micrometastasis detection, J Pathol, 213, 180, 10.1002/path.2229 St Croix, 2000, Genes expressed in human tumor endothelium, Science, 289, 1197, 10.1126/science.289.5482.1197 Streit, 1999, Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis, Proc Natl Acad Sci USA, 96, 14888, 10.1073/pnas.96.26.14888 Strongin, 2010, Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy, Biochim Biophys Acta, 1803, 133, 10.1016/j.bbamcr.2009.04.009 Svensson, 1997, CGP 48664, a potent and specific S-adenosylmethionine decarboxylase inhibitor: effects on regulation and stability of the enzyme, Biochem J, 322, 297, 10.1042/bj3220297 Svensson, 2008, Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase, Cancer Res, 68, 9291, 10.1158/0008-5472.CAN-08-2340 Takigawa, 1990, Tumor angiogenesis and polyamines: alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro, Cancer Res, 50, 4131 Takigawa, 1990, Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2), Biochem Biophys Res Commun, 171, 1264, 10.1016/0006-291X(90)90822-5 Talts, 1998, Expansion of the nonadherent myeloid cell population by monoclonal antibodies against tenascin-C in murine long-term bone marrow cultures, Exp Hematol, 26, 552 Tikhonenko, 1996, Viral myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene, J Biol Chem, 271, 30741, 10.1074/jbc.271.48.30741 Toft, 2001, Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression, Proc Natl Acad Sci USA, 98, 13055, 10.1073/pnas.231364798 Vollmer, 1997, Biologic and oncologic implications of tenascin-C/hexabrachion proteins, Crit Rev Oncol Hematol, 25, 187, 10.1016/S1040-8428(97)00004-8 Volpert, 1998, A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1, Proc Natl Acad Sci USA, 95, 6343, 10.1073/pnas.95.11.6343 Wallace, 2007, Targeting polyamine metabolism: a viable therapeutic/preventative solution for cancer?, Expert Opin Pharmacother, 8, 2109, 10.1517/14656566.8.13.2109 Watnick, 2003, Ras modulates myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis, Cancer Cell, 3, 219, 10.1016/S1535-6108(03)00030-8 Weinstat-Saslow, 1994, Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis, Cancer Res, 54, 6504 Yang, 2007, Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma, Cancer Res, 67, 1716, 10.1158/0008-5472.CAN-06-2595 Zabrenetzky, 1994, Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines, Int J Cancer, 59, 191, 10.1002/ijc.2910590209 Zhang, 2007, Thrombospondin-based antiangiogenic therapy, Microvasc Res, 74, 90, 10.1016/j.mvr.2007.04.007 Zhang, 2003, Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation, Proc Natl Acad Sci USA, 100, 12718, 10.1073/pnas.2135113100